Overview

Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)

Status:
Active, not recruiting

Trial end date:
2022-06-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to see if a treatment regimen with a combination of paclitaxel protein bound (also known as nab-paclitaxel), gemcitabine, and cisplatin when given with high dose Ascorbic Acid will be safe and effective in individuals with untreated metastatic pancreatic cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

HonorHealth Research Institute

Collaborators:

Barts Cancer Institute
Cancer Research UK
Cancer Research UK (CRUK)
Cold Spring Harbor Laboratory
Imaging Endpoints
Lustgarten Foundation
Princeton University
Salk Institute for Biological Studies
Stand Up To Cancer
Translational Genomics Research Institute
University of Arizona

Treatments:

Albumin-Bound Paclitaxel
Ascorbic Acid
Cisplatin
Gemcitabine
Paclitaxel